COMP <GO>
PBYI vs MRK // REVENUE GROWTH (YOY)
Puma Biotechnology Inc (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: PBYI 6
— MRK 7
▲ REVENUE GROWTH (YOY) LEADER: MRK
LAST: $10.44 (-0.95%) • MKT CAP: $544.1M
revenue-growth
-0.90%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
revenue-growth
1.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PBYI VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PBYI | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.50% | 74.80% | -0.30 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.30% | 20.70% | +8.60 | PBYI | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.8x | 15.3x | -1.50 | PBYI | /valuation <GO> |
| Free Cash Flow Yield | 7.67% | 3.42% | +4.25 | PBYI | /fcf-yield <GO> |
| Operating Margin | 16.30% | 34.30% | -18.00 | MRK | /operating-margins <GO> |
| Net Profit Margin | 13.60% | 28.10% | -14.50 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -0.90% | 1.30% | -2.20 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.19 | -4.99 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | PBYI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.5 | 51.7 | +2.80 | PBYI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 16.3x | 18.4x | -2.10 | PBYI | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $544.1M | $361.02B | -$360.48B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PBYI REV | MRK REV | PBYI GROSS % | MRK GROSS % | PBYI FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $228.4M | $65.01B | 74.5% | 74.8% | $41.7M | $12.36B |
| FY 2024 | $230.5M | $64.17B | 72.1% | 76.3% | $38.9M | $18.10B |
| FY 2023 | $235.6M | $60.12B | — | — | $27.0M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PBYI // BETA —
MRK // BETA 0.92